Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Santhera Pharmaceuticals AG 

Im Neuenheimer Feld 518 - 519

Heidelberg    69120  Germany
Phone: 49-0-6221-649-33-0 Fax: 49-0-6221-649-3311



 Company News
Parent Project Muscular Dystrophy And Santhera Pharmaceuticals AG (SANN.SW) Team Up On Benefit/Risk Study In Duchenne 11/25/2014 9:22:00 AM
Switzerland-Based Santhera Pharmaceuticals AG (SANN.SW) Grabs CHF 13.4 Million 8/15/2014 6:37:50 AM
Santhera Pharmaceuticals AG (SANN.SW) Reports Positive Outcome For Catena®/Raxone® In Phase 3 DMD Trial Supported By Additional Respiratory Function Data 5/22/2014 9:59:59 AM
Santhera Pharmaceuticals AG (SANN.SW) Announces Successful Outcome Of Phase 3 Study With Catena®/Raxone® In Duchenne Muscular Dystrophy 5/13/2014 7:00:00 AM
Santhera Pharmaceuticals AG (SANN.SW) Plunges on European Eye Drug Rejection 1/18/2013 7:37:43 AM
Santhera Pharmaceuticals AG (SANN.SW) and Ipsen Renegotiate Fipamezole Licensing Agreement 1/24/2012 6:02:17 AM
Santhera Pharmaceuticals AG (SANN.SW) and Ipsen Enter into Licensing Agreement for Fipamezole for the Treatment of Dyskinesia in Parkinson's Disease; Upfront Payment of 13 Million Euros With Another Milestones of Up To 128 Million Euros 9/3/2010 7:26:17 AM
Santhera Pharmaceuticals AG (SANN.SW) Eyes Approval of Lead Drug, Catena in First Half of 2011 6/16/2010 7:00:01 AM
Santhera Pharmaceuticals AG (SANN.SW)'s MICONOS Trial with Catena/Sovrima in Friedreich's Ataxia Misses Phase 3 Primary Endpoint 5/20/2010 7:33:26 AM
Biovail Pharmaceuticals, Inc., Santhera Pharmaceuticals AG Strike Parkinson's Drug Deal; Santhera Could Pay up to $184 Million 8/24/2009 6:32:40 AM